
Sarepta Therapeutics, Inc.
SRPTHealthcare|Biotechnology|US
$17.82
+0.25 (+1.42%)
Tangible Book / Share
$14.15
Graham Number
$6.73
Cash / Share
$8.30
Next Earnings Report
Feb 24, 2027
EPS est. -$0.06 · Revenue est. $351.4M
Financing Filings (last 12 months)
0
No shelf registrations or offering prospectuses filed.
Upcoming Data Readouts (7)
Nov 2026
Est. completion
May 2027
Est. completion
P3Duchenne Muscular Dystrophy
A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Non-Ambulatory and Ambulatory Participants With Duchenne Muscular Dystrophy (DMD)
NCT05881408n=148
Aug 2027
Est. completion
P4Duchenne Muscular Dystrophy
Study to Evaluate the Safety and Effectiveness of ELEVIDYS in Participants With Duchenne Muscular Dystrophy Treated in a Post-Marketing Setting
NCT07542314n=20
Nov 2027
Est. completion
P1Huntington's Disease
A First-in-human Study of the Effects of SRP-1005 in Participants With Huntington's Disease
NCT07536061n=32
Dec 2027
Est. completion
P1Duchenne Muscular Dystrophy
A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD) - Non-Ambulatory Cohort
NCT04626674n=83
Aug 2028
Est. completion
P1Limb Girdle Muscular Dystrophy
A Gene Transfer Single Dose Study to Evaluate the Safety, Tolerability and Efficacy of SRP-9003 in Non-Ambulatory and Ambulatory Participants With Limb Girdle Muscular Dystrophy, Type 2E/R4 (Beta-Sarcoglycan [β-SG] Deficiency)
NCT05876780n=6
Sep 2030
Est. completion
Limb-girdle Muscular Dystrophy
A Study of the Natural History of Participants With LGMD2E/R4, LGMD2D/R3, LGMD2C/R5, and LGMD2A/R1 ≥ 4 Years of Age, Who Are Managed in Routine Clinical Practice
NCT04475926n=205
Awaiting Results (3)
Trials past primary completion date but still active — data readout may be imminent.
Oct 2026
P3
A Study to Compare Safety and Efficacy of High Doses of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD) (MIS51ON)
NCT03992430Mar 2026
P2
A Gene Delivery Study to Evaluate the Safety and Expression of Delandistrogene Moxeparvovec in Participants Under the Age of Four With Duchenne Muscular Dystrophy (DMD)
NCT06128564Mar 2025
P3
A Trial to Learn More About an Experimental Gene Therapy Called Bidridistrogene Xeboparvovec (SRP-9003) as a Possible Treatment for Limb Girdle Muscular Dystrophy 2E/R4
NCT06246513Recent Press Releases
Sarepta Therapeutics Announces Third Quarter 2026 Financial Results and Recent Corporate Developments
Nov 5, 2026 · Business Wire
Sarepta Therapeutics to Present at Upcoming Investor Conferences
Oct 26, 2026 · Business Wire
Sarepta Therapeutics to Announce Third Quarter 2026 Financial Results
Oct 22, 2026 · Business Wire
Sarepta Therapeutics Presents New Preclinical Data Demonstrating Robust Knockdown of Pathogenic DMPK RNA in the Nucleus with SRP-1003 in DM1 at 2026 Oligonucleotide Therapeutics Society Annual Meeting
Oct 14, 2026 · Business Wire
Sarepta Therapeutics Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Sarepta Therapeutics, Inc. - SRPT
Oct 5, 2026 · Business Wire
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sep 30, 2026 · Business Wire
Sarepta Therapeutics Presents New Data at 2026 World Muscle Society Annual Congress Demonstrating Safety and Clinically Meaningful Functional Benefit of ELEVIDYS (delandistrogene moxeparvovec) in Older Ambulatory Patients with Duchenne
Sep 30, 2026 · Business Wire
Sarepta Therapeutics Announces Presentations at 2026 World Muscle Society Annual Congress
Sep 25, 2026 · Business Wire
SEC Filings (64)
Last two years from EDGAR. Insider Form 4s are on the Ownership tab.
| Filed | Form | What it is | Links |
|---|---|---|---|
| Nov 5, 2026 | 8-K | Material event | DocumentIndex |
| Nov 5, 2026 | 10-Q | Quarterly report | DocumentIndex |
| Sep 23, 2026 | 8-K | Material event | DocumentIndex |
| Aug 14, 2026 | 13F-HR | Institutional holdings report | DocumentIndex |
| Aug 13, 2026 | SC 13G/A | Passive 5%+ stake | DocumentIndex |
| Aug 7, 2026 | SC 13G | Passive 5%+ stake | DocumentIndex |
| Aug 5, 2026 | 8-K | Material event | DocumentIndex |
| Aug 5, 2026 | 10-Q | Quarterly report | DocumentIndex |
| Jul 31, 2026 | SC 13G/A | Passive 5%+ stake | DocumentIndex |
| Jul 30, 2026 | SC 13G/A | Passive 5%+ stake | DocumentIndex |
| Jul 28, 2026 | S-8 | Employee stock plan | DocumentIndex |
| Jul 27, 2026 | 8-K | Material event | DocumentIndex |
| Jun 4, 2026 | S-8 | Employee stock plan | DocumentIndex |
| Jun 4, 2026 | 8-K | Material event | DocumentIndex |
| May 13, 2026 | 13F-HR | Institutional holdings report | DocumentIndex |
| May 6, 2026 | 8-K | Material event | DocumentIndex |
| May 6, 2026 | 10-Q | Quarterly report | DocumentIndex |
| Apr 30, 2026 | SC 13G | Passive 5%+ stake | DocumentIndex |
| Apr 29, 2026 | SC 13G | Passive 5%+ stake | DocumentIndex |
| Apr 24, 2026 | ARS | Annual report to holders | DocumentIndex |
| Apr 24, 2026 | DEFA14A | Proxy / shareholder vote | DocumentIndex |
| Apr 24, 2026 | DEF 14A | Proxy / shareholder vote | DocumentIndex |
| Mar 27, 2026 | SC 13G/A | Passive 5%+ stake | DocumentIndex |
| Mar 2, 2026 | 10-K | Annual report | DocumentIndex |
| Feb 25, 2026 | 8-K | Material event | DocumentIndex |
| Feb 25, 2026 | 8-K | Material event | DocumentIndex |
| Feb 13, 2026 | SC 13G | Passive 5%+ stake | DocumentIndex |
| Feb 13, 2026 | 13F-HR | Institutional holdings report | DocumentIndex |
| Jan 21, 2026 | SC 13G/A | Passive 5%+ stake | DocumentIndex |
| Jan 12, 2026 | 8-K | Material event | DocumentIndex |
| Dec 19, 2025 | 8-K | Material event | DocumentIndex |
| Dec 11, 2025 | 8-K | Material event | DocumentIndex |
| Dec 8, 2025 | 8-K | Material event | DocumentIndex |
| Nov 14, 2025 | SC 13G/A | Passive 5%+ stake | DocumentIndex |
| Nov 10, 2025 | SC 13G | Passive 5%+ stake | DocumentIndex |
| Nov 6, 2025 | 10-Q | Quarterly report | DocumentIndex |
| Nov 3, 2025 | 8-K | Material event | DocumentIndex |
| Sep 8, 2025 | SC 13G/A | Passive 5%+ stake | DocumentIndex |
| Aug 29, 2025 | 8-K | Material event | DocumentIndex |
| Aug 21, 2025 | 8-K | Material event | DocumentIndex |